Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

Int J Obes (Lond) · 2016 · PMC4973216 · PMID 27005405

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

of borderline significanceP =0.05actually significant

The reduction in high-sensitivity C-reactive protein with liraglutide was of borderline significance versus placebo ( P =0.05).

also in 1,681 other papers

an overall trendno p-value reported

The precise clinical significance of the 12 events h −1 mean reduction in AHI with liraglutide is unclear, but consistent positive changes in supportive secondary end points related to sleep apnea and cardiovascular risk factors indicate an overall trend toward improvement.

also in 3,038 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.